Saitama Medical University · Faculty of Medicine / Graduate School of Medicine · 教授

Research keywordsbreast cancer endocrine therapy・ER-positive HER2-negative breast cancer・metaplastic breast cancer・platinum-based neoadjuvant chemotherapy・psycho-oncology communication・informed consent in chemotherapy・AFP-producing gastric cancer

Research fields血液、腫瘍内科学

This is a public-data preview. Personalized fit, contact angles, and saved workflows require sign-in.

• Economic evaluation of the 70-gene prognosis-signature (MammaPrint(A (R))) in hormone receptor-positive, lymph node-negative, human epidermal growth factor receptor type 2-negative early stage breast cancer in Japan
• 【妊娠中に発見された悪性腫瘍の取り扱い】 妊娠中に発見される乳癌
• Tumor-derived interleukin (IL)-6 induced anti-tumor effect in immune-compromised hosts
• A randomized, double-blind, placebo-controlled phase II study of olanzapine based prophylactic antiemetic therapy for delayed and persistent nausea and vomiting in patients with HER2-positive or HER2-low breast cancer treated with trastuzumab deruxtecan: ERICA study (WJOG14320B)

• 2022/06～2025/07 転移・再発乳癌における 遺伝子パネル検査FoundationOne® CDxと FoundationOne® Liquid CDxの 治療方針決定に与える影響を 検討する観察研究2022 · 研究課題・受託研究・科研費
• 2022/08～ A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND SAFETY OF NIRAPARIB TO PLACEBO IN PARTICIPANTS WITH EITHER HER2- NEGATIVE BRCA-MUTATED OR TRIPLE-NEGATIVE BREAST CANCER WITH MOLECULAR DISEASE BASED ON PRESENCE OF CIRCULATING TUMOR DNA AFTER DEFINITIVE THERAPY (ZEST) 企業からの受託研究2022 · 研究課題・受託研究・科研費
• 2022/07～ 高リスクHER2陽性早期乳癌の患者を対象とする術前薬物療法としてトラスツズ マブ デルクステカン(T-DXd)単剤療法又はT-DXd後THP投与とddAC-THP投与を 比較する第III相非盲検試験(DESTINY-Breast11試験) 企業からの受託研究2022 · 研究課題・受託研究・科研費
• 2021/02～2029/12 進行・再発乳癌データベースプロジェクト2021 · 研究課題・受託研究・科研費

• Official profile